Xtant Medical Holdings, Inc. (XTNT)

NYSEAMERICAN: XTNT · Real-Time Price · USD
0.505941
+0.0243 (5.05%)
Apr 20, 2026, 11:49 AM EDT - Market open
Market Cap70.87M +8.4%
Revenue (ttm)133.93M +14.2%
Net Income4.97M
EPS0.03
Shares Out 140.07M
PE Ratio16.82
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume30,605
Open0.4818
Previous Close0.4816
Day's Range0.4816 - 0.5019
52-Week Range0.3901 - 0.9500
Beta-0.16
AnalystsStrong Buy
Price Target1.00 (+97.65%)
Earnings DateMay 11, 2026

About XTNT

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFact... [Read more]

Sector Healthcare
CEO Sean Browne
Employees 232
Stock Exchange NYSEAMERICAN
Ticker Symbol XTNT
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to one analyst, the rating for XTNT stock is "Strong Buy" and the 12-month stock price target is $1.0.

Price Target
$1.0
(97.65% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product

Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont...

7 days ago - PRNewsWire

Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial

BELGRADE, Mont., April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced suppor...

11 days ago - PRNewsWire

Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results

Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 3...

20 days ago - PRNewsWire

Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026

BELGRADE, Mont., March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic condition...

26 days ago - PRNewsWire

Xtant Medical Finalizes Companion Spine Transactions

Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xta...

7 weeks ago - PRNewsWire

Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference

BELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthop...

7 weeks ago - PRNewsWire

Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft

nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mo...

4 months ago - PRNewsWire

Xtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine

BELGRADE, Mont. , Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic con...

4 months ago - PRNewsWire

Xtant Medical Reports Third Quarter 2025 Financial Results

Total Revenue of $33.3 Million Increased 19% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Reiterates FY25 Revenue Guidance of $131-$135 Million, Representing Gr...

5 months ago - PRNewsWire

Xtant Medical Announces Commercial Launch of CollagenX™

Launch further expands Xtant's biologics product portfolio to include surgical wound closure BELGRADE, Mont. , Nov. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global...

5 months ago - PRNewsWire

Xtant Medical to Announce Third Quarter 2025 Financial Results on November 11, 2025

BELGRADE, Mont. , Nov. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthop...

5 months ago - PRNewsWire

Xtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

BELGRADE, Mont. , Sept. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, ortho...

8 months ago - PRNewsWire

Xtant Medical Reports Second Quarter 2025 Financial Results

Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth...

8 months ago - PRNewsWire

Xtant Medical to Attend the CG 45th Annual Growth Conference

BELGRADE, Mont. , Aug. 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthop...

9 months ago - PRNewsWire

Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025

BELGRADE, Mont., Aug. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthope...

9 months ago - PRNewsWire

Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine

Transaction expected to facilitate enhanced focus on Xtant's core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, ...

10 months ago - PRNewsWire

Xtant Medical Announces the Launch of OsteoFactor Pro™

Allogeneic Growth Factor Solution to Accelerate Bone Repair BELGRADE, Mont. , May 28, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focus...

11 months ago - PRNewsWire

Xtant Medical Reports First Quarter 2025 Financial Results

Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont. , May 12, 2025...

1 year ago - PRNewsWire

Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

BELGRADE, Mont. , May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthope...

1 year ago - PRNewsWire

Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance

BELGRADE, Mont. , April 23, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc.(NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthop...

1 year ago - PRNewsWire

Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches BELGRADE, Mont. , April 16, 2025 /PRNewswire/ -- Xt...

1 year ago - PRNewsWire

Xtant Medical Reports Fourth Quarter and Full Year 2024 Financial Results

Full Year 2024 Revenue Growth of 28% Expects 2025 Revenue of $126 Million to $130 Million Without Need for Additional Capital BELGRADE, MT / ACCESS Newswire / March 6, 2025 / Xtant Medical Holdings, I...

1 year ago - Accesswire

Xtant Medical to Issue Fourth Quarter and Year End 2024 Financial Results on March 6, 2025

BELGRADE, MT / ACCESS Newswire / February 28, 2025 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal di...

1 year ago - Accesswire

Xtant Medical Reports Third Quarter 2024 Financial Results

Third Quarter Revenue Growth of 12% Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million Representing Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Me...

1 year ago - Accesswire

Xtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select Conference

BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorde...

1 year ago - Accesswire